TNF and type I IFN induction of the IRG1-itaconate pathway restricts Coxiella burnetii replication within mouse macrophages

The intracellular Gram-negative bacterium Coxiella burnetii replicates within macrophages and causes a zoonotic disease known as Q fever. In murine macrophages, the cytokine tumor necrosis factor (TNF) is critical for restriction of intracellular C. burnetii replication. Here, we show that TNF collaborates with type I interferon (IFN) signaling for maximal control of C. burnetii. We found that TNF and type I IFN upregulate the expression of the metabolic enzyme immune responsive gene 1 (IRG1), also known as cis-aconitate decarboxylase 1 (ACOD1), and that IRG1 is required to restrict C. burnetii T4SS translocation and replication within macrophages. Further, we show that itaconic acid, the metabolic product of IRG1, restricts C. burnetii replication both intracellularly and in axenic culture. These data reveal that TNF and type I IFN upregulate the IRG1-itaconate pathway to restrict intracellular C. burnetii replication within murine macrophages.


Introduction
The Gram-negative facultative intracellular bacterium Coxiella burnetii is the causative agent of the zoonotic disease known as Q fever (1). Often asymptomatic, Q fever presents as an acute atypical pneumonia, and can develop into a long-term chronic infection that can lead to hepatitis or endocarditis, with an increased risk of severe disease to individuals with immunodeficiencies or heart issues and pregnant women (2,3). Q fever occurs worldwide and is a significant public health concern with periodic outbreaks, such as one that occurred in the Netherlands from 2007-2010 with over 4,000 cases (4)(5)(6)(7)(8)(9). C. burnetii is classified as a category B pathogen due to its aerosol mode of transmission and environmental stability (10). Despite this potentially severe threat to human health, the mechanisms underlying how C. burnetii interacts with host cells and the critical host factors that restrict bacterial replication remain poorly understood.
The predominant reservoir for C. burnetii is domesticated livestock, and the bacteria can easily be transmitted to human hosts via aerosolized secretions (9). Upon inhalation into the lung, C. burnetii is taken up primarily by resident alveolar macrophages (11, 12). Following internalization, C. burnetii engages both the endolysomal and autophagic pathways (13-15) to form its replicative compartment known as the Coxiella-containing vacuole or CCV (16). Full acidification and maturation of this phagolysosome is necessary to stimulate bacterial metabolism and to activate the C. burnetii Type IVb Secretion System (T4SS), which delivers over 100 effector proteins to manipulate the host cell (17)(18)(19). The T4SS is required for replication as well as maintenance and expansion of the CCV (20-22).
Macrophages employ pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), to detect pathogen-associated molecular patterns (PAMPs) (23, 24). In particular, TLR2 signaling is important for controlling the intracellular replication of C. burnetii within murine macrophages (25, 26). We previously found that TLR2-driven restriction of C. burnetii within macrophages was dependent on production of the pro-inflammatory cytokine Tumor Necrosis Factor (TNF) (27). In other contexts, TNF can promote a variety of immune responses, including transcription of inflammatory mediators and induction of cell death (28-30). TNF binding to its receptors TNFR1 and TNFR2 can trigger a signaling cascade that upregulates many genes and antimicrobial programs (31), but can also be a key driver of pathologic inflammation. Thus, anti-TNF therapy is a frequent treatment for autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and multiple sclerosis. However, patients on TNF blockade are more susceptible to intracellular bacterial pathogens, including Mycobacterium, Listeria, Legionella,Salmonella,. Surprisingly, the mechanisms underlying how TNF restricts C. burnetii and other intracellular bacterial pathogens are not fully understood.
Here, we find that maximal TNF-dependent restriction of C. burnetii replication relies on basal type I interferon (IFN) signaling in murine macrophages. Furthermore, we show that TNF and IFN collaborate to induce maximal expression of the host gene Immune Responsive Gene 1 (Irg1). Irg1 encodes a cis-aconitate decarboxylase (ACOD1) that converts the TCA intermediate aconitate into itaconate, which possesses antimicrobial activity against intracellular pathogens including L. pneumophila, M. tuberculosis, and Salmonella (35)(36)(37) Our data indicate that IRG1 mediates TNF and IFN-mediated restriction of C. burnetii T4SS translocation and replication within murine macrophages. Addition of itaconate to Irg1 -/cells restored inhibition of C. burnetii T4SS secretion and intracellular replication. Furthermore, itaconate was sufficient to inhibit bacterial replication in axenic cultures. Overall, our findings reveal that TNF and type I IFN signaling collaborate to induce IRG1 expression, and that IRG1 is required for TNF and type I IFN-dependent restriction of C. burnetii in murine macrophages. Collectively, these findings provide important insight into the mechanisms underlying how TNF restricts C. burnetii replication within murine macrophages.

Bacterial culture conditions
All experiments were conducted using variants of the avirulent Nine Mile Phase II (NMII) strain of Coxiella burnetii (RSA 439, Clone 4): wild-type (WT) C. burnetii, WT C. burnetii expressing mCherry (38), an icmL:Tn strain with a non-functional T4SS due to a transposon insertion in the icmL gene (20), and WT and icmL:Tn strains harboring a plasmid encoding blaM alone or blaM fused to the T4SS effector gene CBU_0077 (20). The bacteria were cultured in acidified citrate cysteine medium 2 (ACCM-2; Sunshine Scientific Products) (39) at a starting concentration of 2x10 6 bacteria/ml for 7 days at 37°C and 5% CO2 and 2.5% O2. One day after inoculation, kanamycin (275 mg/ml) was added to the icmL:Tn cultures and chloramphenicol (3 mg/ml) was added to the cultures of the strains containing the BlaM-or BlaM-0077-expressing plasmids. After 7 days, the cultures were quantified by isolating the genomic DNA from 1ml of inoculate using GenElute Bacterial Genomic DNA kit (Sigma) and measuring the genomic equivalents (GE) by quantitative PCR (qPCR) using primers for C. burnetii dotA gene (FWD: GCGCAATACGCTCAATCACA and REV: CCATGGCCCCAATTCTCT). The plasmid pGEM-T encoding the C. burnetii dotA gene was serially diluted and used to generate a standard curve for qPCR to enable the calculation C. burnetii genome equivalents. For growth assays of C. burnetii axenic cultures, pharmacological agents were added to the ACCM at the time of inoculation or at a time otherwise specified.

Flow cytometry
For experiments assaying T4SS injection into BMDMs, the C. burnetii strains harboring blaM or blaM-0077 plasmids were used, Infected cells were harvested using cold PBS with 2mM EDTA and pelleted at 2500 rpm at 4°C, then resuspended in PBS with 2mM EDTA and 2% BSA. Cells were then loaded with CCF4-AM for 2 hours at room temperature using the LiveBLAzer Fret-B/G Loading with CCF4-AM kit from Thermo Fisher. After 2 hours, cells were fixed with BD Cytofix (BD Biosciences). Fixed cells were then analyzed on a LSR II flow cytometer (BD Biosciences), and the data were further analyzed using FlowJo analysis software (TreeStar).

Fluorescence microscopy
For microscopic imaging of WT C. burnetii expressing mCherry during infection of macrophages, approximately 2.5 x 10 5 BMDM cells were seeded onto glass coverslips in 24well plates and infected as described above. To collect samples for imaging, coverslips were washed gently with PBS, fixed in 4% paraformaldehyde in PBS, permeabilized with 0.2% Triton-X, then washed with PBS and mounted on glass slides using Fluoroshield with Dapi (Sigma). Slides were imaged on an Olympus IX81 inverted fluorescence microscope and analyzed and presented using SlideBook software (Intelligent Imaging Innovations, Inc.).
burnetii was able to replicate within macrophages following the removal of rTNF treatment at 24 hours post-infection (Fig. 1B). Collectively, these data indicate TNF inhibits C. burnetii replication within BMDMs, in agreement with our previous findings (27).
TNF signals through two distinct receptors, TNF receptor 1 (TNFR1) or TNF receptor 2 (TNFR2). TNFR1 signaling is associated with many potential antimicrobial effector mechanisms, such as inflammatory signaling, induction of cell death, and production of reactive oxygen and nitrogen species, while TNFR2 signaling is associated with cell proliferation, adhesion, and survival (29,41). Notably, Tnfr1 -/-BMDMs were significantly more permissive for C. burnetii intracellular replication than WT BMDMs (Fig. 1C). Moreover, exogenous rTNF addition could not rescue restriction of C. burnetii in Tnfr1 -/-BMDMs (Fig. 1C). In contrast, C. burnetii replicated within Tnfr2 -/-BMDMs to a similar extent as within WT BMDMs and was similarly restricted by exogenous rTNF treatment. Collectively, these data indicate that TNF signaling through TNFR1, not TNFR2, mediates restriction of C. burnetii replication within murine macrophages.

TNF signaling suppresses T4SS effector translocation
T4SS-dependent translocation of effectors into host cells is necessary for establishment of the Coxiella-containing vacuole and subsequent bacterial replication (20). TNF signaling could potentially restrict C. burnetii replication by blocking T4SS-dependent translocation of effector proteins. To test the possibility that TNF suppresses T4SS-dependent translocation, we employed a fluorescence resonance energy transfer (FRET)-based reporter system in conjunction with C. burnetii harboring a plasmid encoding E. coli TEM-1 ß-lactamase (BlaM) translationally fused to the effector Cbu_0077 (pBlaM-0077) (20). After 24 hours of infection with this strain, BMDMs are loaded with the cell-permeable fluorescent substrate CCF4-AM, which consists of coumarin joined to fluorescein by a b-lactam ring. 409-nm excitation of CCF4-AM results in FRET between coumarin and fluorescein and green fluorescence emission at 518 nm. T4SS-injected BlaM-0077 cleaves CCF4AM and eliminate FRET, resulting in blue fluorescence emission at 447 nm. Injected cells can be distinguished from uninjected cells using flow cytometry.

TNF-mediated restriction of C. burnetii replication occurs independently of cell death and reactive nitrogen and oxygen species
TNF signaling can elicit various antimicrobial programs and cell fates. One such response is the activation of different cell death pathways, which can result in elimination of infected cells (31, 42). TNFR1 signaling can also promote activation of RIPK1's kinase activity (43), leading to either caspase-8-dependent apoptosis or RIPK3-dependent programmed necrosis (44,45). To examine whether these death pathways contribute to TNF-dependent restriction of C. burnetii infection, we derived BMDMs from Ripk3 -/or Casp8 -/-Ripk3 -/mice. BMDMs from Casp8 -/-Ripk3 -/mice must be utilized to examine the role of caspase-8 because Casp8 -/mice are embryonic lethal (46). Unexpectedly, in untreated BMDMs, Ripk3 -/-BMDMs were significantly more permissive for C. burnetii replication, indicating a possible role for RIPK3 in restricting C. burnetii. However, exogenous TNF was still able to restrict intracellular C. burnetii replication in the absence of RIPK3 or both CASP8 and RIPK3 ( Fig. 2A), indicating that both CASP8 and RIPK3 are dispensable for TNF-mediated restriction. BMDMs derived from RIPK1-kinase dead (Ripk1 KD ) mice, which lack RIPK1 kinase activity but retain other RIPK1 signaling functions (47), also restricted C. burnetii replication following rTNF treatment (Fig. 2B). Following infection with C. burnetii expressing BlaM-0077, we observed that the percentage of T4SS-injected cells was also significantly decreased in Casp8 -/-Ripk3 -/cells treated with rTNF, similarly to WT BMDMs (Fig. S2). Collectively, these data indicate that the caspase-8-mediated apoptosis and necroptosis pathways do not contribute to TNF-driven restriction of C. burnetii T4SS translocation or replication within macrophages.
TNF signaling can upregulate expression of inducible nitric oxide synthase (iNOS, also known as NOS2) (48) to generate the reactive metabolite nitric oxide (49), which can restrict C. burnetii replication in cell lines (50, 51). TNF can also activate NADPH oxidase to generate superoxide (O2-) that can be converted into membrane-permeable hydrogen peroxide (H2O2) (52), which can restrict the growth of various intracellular bacteria, including C. burnetii (50, 53). To determine whether NADPH oxidase and/or iNOS play a role in TNF-mediated restriction of C. burnetii, we infected BMDMs from mice lacking Nos2 or Gp91phox, which encodes a subunit of NADPH oxidase (52). Though Gp91phox -/macrophages were generally more permissive than WT BMDMs, both Gp91phox -/and Nos2 -/-BMDMs still restricted C. burnetii intracellular replication to levels similar to those observed in WT BMDMs following rTNF treatment (Fig. 2C). Consistently, TNF treatment also restricted C. burnetii T4SS injection in Gp91phox -/and Nos2 -/-BMDMs comparably to WT BMDMs (Fig. S2). These data indicate that neither iNOS nor NADPH oxidase is required for TNF-driven restriction of C. burnetii T4SS translocation or replication.

Type I interferon and TNF collaborate to restrict C. burnetii intracellular replication
We have previously found that C. burnetii infection of BMDMs induces low, but biologically active levels of type I IFN (27). Like TNF, type I IFNs can induce antimicrobial programs in host cells to restrict bacterial replication and spread (54). Typically, type I IFNs are induced downstream of microbial stimulation of TLRs or cytosolic sensors (55, 56). Furthermore, type I IFNs can synergize with TNF in both a paracrine and autocrine manner to strongly induce and maintain immune responses during infection (57). To investigate the potential role of type I IFNs in promoting TNF-mediated restriction of C. burnetii infection, we infected BMDMs lacking the type I IFN receptor IFNAR1. We found that while Ifnar -/-BMDMs were significantly more permissive than WT BMDMs, intracellular C. burnetii replication was still significantly reduced by TNF treatment (Fig. 3A & B). This restriction, however, was not to the same extent observed with WT BMDMs, as C. burnetii replicated within TNF-treated Ifnar -/-BMDMs to the same extent as untreated WT BMDMs (Fig. 3A). Interestingly, Coxiella T4SS injection levels were significantly higher in Ifnar -/-BMDMs compares to WT, yet both WT and Ifnar -/-BMDMs showed similar decreases in the percentage of T4SS-injected cells following TNF treatment (Fig. 3C & D), indicating that TNF restricts T4SS translocation independently of IFNAR1 signaling.
To further define the effects of type I IFN on C. burnetii replication, we treated WT BMDMs with recombinant interferon-a (rIFNa) and observed suppression of bacterial restriction similar to that observed with TNF treatment (Fig. 3E). Interestingly, rIFNa treatment of Tnf -/-BMDMs led only to partial restriction of C. burnetii replication (Fig. 3E), indicating that TNF is required for maximal restriction of C. burnetii by type I IFN. We similarly observed that Tnfr1 -/-BMDMs treated with rIFNa were unable to fully restrict C. burnetii replication (Fig. 3F). Taken together, these data indicate that type I IFN synergizes with TNF signaling to restrict C. burnetii replication within macrophages.

TNF and IFN upregulate IRG1 to suppress C. burnetii replication in murine macrophages
Given that both TNF and type I IFN are required to restrict C. burnetii within murine macrophages, we next considered antimicrobial host factors that could be regulated by both TNF and type I IFN. The enzyme immune-responsive gene 1 (IRG1) also known as cisaconitate decarboxylase 1 (ACOD1) catalyzes the conversion of the TCA cycle intermediate aconitate into itaconate and is upregulated by a variety of pro-inflammatory cytokines, including both TNF and type I IFN (35,58). IRG1 contributes to the restriction of intracellular pathogens, including Salmonella enterica, M. tuberculosis and L. pneumophila (59, 60). In both WT and Tnf -/-BMDMs, Irg1 mRNA expression was induced by either exogenous TNF treatment or C. burnetii infection, and it was induced even more so by both together (Fig. 4A). Irg1 was also induced in Ifnar -/-BMDMs following TNF stimulation and C. burnetii, but to a lower extent than in WT BMDMs (Fig. 4A), indicating that endogenous type I IFN signaling is required for maximal TNF-dependent Irg1 expression. Irg1 induction was also further increased by combined rIFNa and C. burnetii infection in both WT and Tnf -/-BMDMs, but not in Ifnar -/-BMDMs (Fig. 4A). These data indicate that C. burnetii infection induces Irg1 expression, and that Irg1 expression is further enhanced by TNF and type I IFN stimulation.
To test the possible contribution of IRG1 to restricting C. burnetii intracellular replication, we transfected WT BMDMs with siRNA targeting Irg1 or a scrambled control siRNA prior to and during C. burnetii infection. Notably, Irg1 siRNA treatment resulted in a 70-80% knockdown of Irg1 mRNA levels over the course of a one-week infection (Fig. S3A). Critically, Irg1 knockdown resulted in a significant increase in C. burnetii intracellular replication compared to control siRNA-treated cells (Fig. 4B, S3B). Furthermore, Irg1 -/-BMDMs exhibited a significant increase in C. burnetii replication compared to WT BMDMs ( Fig. 4C and D). Importantly, treatment of Irg1 -/-BMDMs with either TNF (Fig. 4C and D) or IFNa (Fig. 4C) failed to restrict C. burnetii replication. Taken together, these results indicate that IRG1 is required for TNF-and type I IFNdriven restriction of C. burnetii intracellular replication in murine macrophages.
Itaconic acid restricts C. burnetii intracellular replication IRG1 encodes a cis-aconitate decarboxylase (ACOD1) that converts the TCA cycle metabolite aconitate into itaconate, also known as itaconic acid (ITA). ITA inhibits the metabolism and growth of bacterial pathogens by targeting critical bacterial metabolic enzymes, including isocitrate lysase, part of the glyoxylate shunt pathway, and methylisocitrate lyase in the 2methylcitrate cycle (59-62). To test whether exogenous ITA can complement IRG1 deficiency and restore restriction of C. burnetii intracellular replication in Irg1 -/-BMDMs, we treated WT or Irg1 -/-BMDMs with low (1 mM) as well as high (10 mM) doses of ITA. Importantly, 10 mM ITA is compatible with physiological doses, as it is similar to the concentration of ITA found in activated RAW264.7 murine macrophage cells (59). Critically, ITA treatment potently restricted C. burnetii replication within both WT and Irg1 -/-BMDMs in a dose-dependent manner ( Fig. 5A and B). We also found that high dose ITA inhibited C. burnetii replication even when added as late as 72 hours post-infection (Figs. 5C, S4). We observed that removal of 1mM, but not 10mM, ITA treatment at 24 or 72 hours following C. burnetii infection allowed for some recovery of bacteria replication, suggesting that ITA acts in a bacteriostatic manner to limit replication ( Fig. 5C and S4). Altogether, these data indicate that ITA restricts C. burnetii replication within macrophages.

Itaconic acid inhibits C. burnetii T4SS translocation and axenic replication
Given that TNF and IFN treatment limit C. burnetii T4SS translocation, we considered the possibility that they do so via production of IRG1-dependent ITA. Indeed, a significantly higher percentage of Irg1 -/-BMDMs were injected compared to WT BMDMs at 24 hours following infection with C. burnetii expressing BlaM-0077, demonstrating that the absence of . CC-BY 4.0 International license available under a was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made The copyright holder for this preprint (which this version posted July 7, 2023. ; IRG1 correlates with increased translocation (Fig. 6A & B). Moreover, IRG1 was required for TNF-dependent blockade of T4SS injection, as TNF treatment was unable to inhibit T4SS injection in Irg1 -/-BMDMs (Fig. 6A). Critically, ITA treatment of either WT or Irg1 -/-BMDMs during infection with BlaM-0077-expressing C. burnetii significantly reduced T4SS injection in both genotypes (Fig. 6A). Collectively these data indicate that ITA and IRG1 mediate TNF-induced blockade of C. burnetii T4SS-injection within BMDMs.
ITA could inhibit Coxiella replication by acting directly on the bacteria, or by enhancing host immune responses. Given that ITA inhibits bacterial metabolic enzymes in multiple bacterial species (59-62), we tested the direct effect of ITA on C. burnetii growth outside of the host cell. We observed that ITA inhibited C. burnetii axenic replication almost completely at concentrations of 1 and 10 mM (Fig. 6C). Interestingly, C. burnetii grown for 3 days in media containing 1mM ITA fully recovered and replicated to high levels when moved to ITA-free media (Fig. 6C); C. burnetii was also able to recover and replicate to some extent after 3 days of incubation in media containing 10mM ITA (Fig. 6D). Taken together, these results indicate that ITA has a direct, dose-dependent inhibitory effect on C. burnetii axenic replication.

Discussion
Tumor necrosis factor (TNF) signaling is a crucial arm of the antimicrobial immune response that mediates restriction of various intracellular bacterial pathogens, including M. tuberculosis, L. monocytogenes, L. pneumophila, and C. burnetii. We show here that TNF synergizes with type I IFNs for maximal restriction of C. burnetii through induction of IRG1. We also found that the IRG1-produced metabolite itaconate (ITA) restricted C. burnetii T4SS translocation and replication within macrophages and during axenic growth. Thus, TNF and type I IFN function through the IRG1-itaconate pathway to restrict C. burnetii replication within the macrophages.
We found that TNF and type I IFN signaling work together to restrict C. burnetii within BMDMs. BMDMs deficient in either TNF or type I IFN signaling were more permissive for C. burnetii replication, indicating that endogenous production of TNF and type I IFN in response to C. burnetii mediates this restriction. Indeed, we have previously found that C. burnetii infection of BMDMs induced very low, albeit biologically active, levels of type I IFN (27). Interestingly, type I IFN signaling also restricts C. burnetii during in vivo infection of mice (63). We also found that exogenous type I IFN was able to restrict C. burnetii in BMDMs as well as exogenous TNF in wild-type cells, but type I IFN and TNF were reciprocally dependent on each other for full restriction. The synergistic relationship of TNF and type I IFN has been shown before in the context of other pathogens like vesicular stomatitis virus (VSV) and Sendai virus (64,65), and type I IFNs themselves are crucial for resistance against the bacterial pathogens group B streptococci (GBS), S. pneumoniae and E. coli, resulting from defective TNF and IFNg in the absence of IFN signaling (66). Notably, TNF and type I interferons can operate in an autocrine loop, whereby TNF signaling stimulates the production and release of IFNs, which can then act back upon the cell and reinforce the immune response (57). Perhaps this type of autocrine loop also contributes to the ability of TNF and type I IFN to restrict C. burnetii replication via upregulation of Immune Responsive Gene 1 (Irg1).
We also found that TNF and type I IFN signaling upregulate expression of the enzyme IRG1 (Immune-Responsive Gene 1). Furthermore, IRG1 was necessary for TNF and type I IFNmediated restriction of C. burnetii intracellular replication in murine bone marrow-derived macrophages. IRG1 has emerged as a key immune effector against both viral and bacterial pathogens, including Zika virus, S. enterica, M. tuberculosis, L. pneumophila (59, 60, 67). IRG1 . CC-BY 4.0 International license available under a was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made The copyright holder for this preprint (which this version posted July 7, 2023. ; converts the TCA metabolite aconitate into itaconate (itaconic acid or ITA). ITA is one of the most abundant metabolites found in activated macrophages and possesses competitive inhibitory properties against various enzymes. Critically, we found that exogenous ITA potently inhibited C. burnetii replication within macrophages at biologically relevant doses (59). Furthermore, ITA potently restricted C. burnetii axenic growth, indicating a direct inhibitory effect by ITA on C. burnetii. Our findings with IRG1 and ITA restricting C. burnetii replication within murine macrophages are in agreement with recent findings by another group (68). They found that C. burnetii infection induced IRG1 expression in a MyD88-dependent manner, and that IRG1 and ITA restrict C. burnetii replication within murine macrophages. Our data indicate that TNF is the likely candidate cytokine produced downstream of TLR/MyD88 signaling that drives IRG1 expression. Furthermore, they also found that Irg1 -/mice have a defect in control of C. burnetii infection in vivo and treatment of Irg1 -/mice with ITA reduced C. burnetii bacterial loads (68). Interestingly, they found that human macrophages produce much less itaconate than murine macrophages, which may explain why human macrophages are much more permissive for C. burnetii replication than murine macrophages (68).
ITA has direct antibacterial effects on other bacterial species, at least in part by inhibiting bacterial metabolic enzymes such as isocitrate lysase, which is part of the glyoxylate shunt pathway, propionyl-CoA carboxylase in the citramalate cycle, as well as methylisocitrate lyase in the 2-methylcitrate cycle (59, 61,62,[69][70][71]. Interestingly, like its close evolutionary relative L. pneumophila, C. burnetii lacks a glyoxylate shunt, but does encode a methylisocitrate lyase (prpB). In the future, it would be of interest to determine whether prpB or other bacterial enzymes are the potential targets of itaconate in C. burnetii.
C. burnetii possesses a number of effectors that block cell death (72-75), and C. burnetii-infected BMDMs do not undergo cell death (27). Consistently, TNF-driven restriction of C. burnetii is not due to CASP8 or RIPK3-mediated cell death of infected cells. Intriguingly, our recent findings reveal that TNF restriction of the evolutionarily related intracellular pathogen L. pneumophila acts through inflammasome-mediated cell death involving caspases-1, 8, and 11 (76). Unlike C. burnetii, which possesses several effectors that potently block apoptosis and inflammasome-mediated cell death, L. pneumophila has not coevolved with mammalian hosts, and therefore does not have effectors that robustly block regulated cell death in mammalian macrophages. Thus, these findings highlight functional differences in how TNF restricts these two pathogens, possibly due to differences in the how these two pathogens target host pathways.
We also found, surprisingly, that NADPH oxidase (NOX) and inducible nitric oxide synthase (iNos) were dispensable for TNF-mediated restriction of C. burnetii in BMDMs. Importantly, however, in the absence of exogenous TNF treatment, Gp91phox -/-BMDMs were significantly more permissive than WT BMDMs, indicating that while NADPH oxidase does not mediate TNF-induced restriction, NADPH oxidase does contribute to basal control of C. burnetii. Notably, Gp91phox -/mice are also more susceptible to for C. burnetii infection (50), highlighting a greater role for ROS in the context of C. burnetii infection. Potentially, these pathways are complementary or redundant; for example, iNOS has recently been shown to act redundantly with five other immune genes, including IRG1, to restrict L. pneumophila downstream of IFNg (60).
In conclusion, our findings indicate that TNF and type I IFN signaling work in concert to upregulate expression of the antimicrobial immunomodulatory enzyme IRG1 to produce the antimicrobial metabolite itaconate, which restricts intracellular C. burnetii replication within . CC-BY 4.0 International license available under a was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made The copyright holder for this preprint (which this version posted July 7, 2023. ; mouse macrophages. Collectively, our findings provide new insight into the mechanisms by which TNF signaling promotes control of intracellular bacterial pathogens. . CC-BY 4.0 International license available under a was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made The copyright holder for this preprint (which this version posted July 7, 2023.   was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made The copyright holder for this preprint (which this version posted July 7, 2023. ; measuring genomic equivalents (GE) by qPCR. Bar graphs show fold change relative to Day 0 GE levels ± SEM. Data from four independent experiment with duplicate or triplicate wells. * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001, and NS = no significance.

Figure 4 TNF and IFNa act through IRG1 to suppress C. burnetii replication in BMDMs. (A) WT,
Tnf -/and Ifnar -/-BMDMs were treated with or without 10 ng/ml rTNF or 10 3 U/ml rIFNa and were then mock-infected or infected with mCherry-expressing WT C. burnetii at an MOI of 50. Expression of Irg1 mRNA relative to the housekeeping gene Gapdh was measured by qPCR. Bar graphs show mean relative expression ± SEM from triplicate wells. Representative of two independent experiments. Statistical significance based on comparison to relative expression in mock untreated cells. (B) WT BMDMs were stimulated with 10 ng/ml rTNF and transfected with control scrambled or Irg1-targeting siRNA prior to infection with mCherry-expressing WT C. burnetii at an MOI of 50. Bacterial uptake and replication were measured at Day 0 and Day 7, respectively, by measuring genomic equivalents (GE) by qPCR. Bar graphs show fold change relative to Day 0 GE levels ± SEM. Shown are the combined data of 4 independent experiments with triplicate wells. (C) WT and Irg1 -/-BMDMs were treated overnight with or without 10 ng/ml rTNF or 10 3 U/ml rIFNa and then infected with mCherry-expressing WT C. burnetii at an MOI of 50. Bacterial uptake and replication were measured at Day 0 and Day 7, respectively, by measuring genomic equivalents (GE) by qPCR. Bar graphs show fold change relative to Day 0 GE levels ± SEM. Shown are the combined data from 4 independent experiments with duplicate or triplicate wells. (D) Representative fluorescence micrographs of infected BMDMs were fixed and stained with DAPI on Day 7 post-infection and imaged at 40X magnification. * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001, and NS = no significance.  burnetii was inoculated into ACCM-2 media, with or without ITA, and incubated for 7 days; for inoculate with ITA, pH was readjusted prior to inoculation with NaOH. In (D), ITA was removed at Day 3 for some inoculates by centrifugation, washing and resuspension in new ACCM-2. At Day 7, 10 and 14, replication was measured by GE via qPCR. Bar graphs show fold change relative to starting inoculate concentration of 2 X 10 6 GE/ml. Shown are the combined data from four independent experiment. * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001, and NS = no significance.

Figure 7
Graphical model of TNF and type I IFN signaling upregulating IRG1, which produces itaconic acid to restrict C. burnetii replication in mouse macrophages. Infection of macrophages by C. burnetii elicits TLR-driven production of TNF, which is secreted extracellularly and signals in a paracrine and autocrine manner. TNF signaling through TNFR1 and type I IFN signaling through IFNAR work in concert to upregulate expression of IRG1, which localizes to the mitochondria to catabolize production of itaconic acid (ITA), which subsequently blocks the replication of C. burnetii in the host cell. Graphical model created with BioRender.com.    Itaconic acid restricts C. burnetii intracellular growth. WT BMDMs were treated with or without 1mM or 10mM itaconic acid (ITA) and were then infected with mCherry-expressing WT C. burnetii at an MOI of 50. ITA was added or removed at 24 and 72 hours post-infection. Bacterial uptake and replication were measure respectively at Day 0 and Day 7 by measuring genomic equivalents (GE) by qPCR. Bar graphs show fold change relative to Day 0 GE levels ± SEM. Shown are the combined data from 3 independent experiment with triplicate wells. . . CC-BY 4.0 International license available under a was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made

Supplemental
The copyright holder for this preprint (which this version posted July 7, 2023.  was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made The copyright holder for this preprint (which this version posted July 7, 2023.   . CC-BY 4.0 International license available under a was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made The copyright holder for this preprint (which this version posted July 7, 2023. . CC-BY 4.0 International license available under a was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made The copyright holder for this preprint (which this version posted July 7, 2023.  was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  Figure 7 . CC-BY 4.0 International license available under a was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made     was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made The copyright holder for this preprint (which this version posted July 7, 2023.  CC-BY 4.0 International license available under a was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made The copyright holder for this preprint (which this version posted July 7, 2023.   was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made The copyright holder for this preprint (which this version posted July 7, 2023.  was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made The copyright holder for this preprint (which this version posted July 7, 2023. ; https://doi.org/10.1101/2023.07.07.548079 doi: bioRxiv preprint